All In Biotech

NDA 021992 · Pf Prism Cv

Pristiq

Desvenlafaxine Succinate · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Feb 29, 2008

Approved uses

3

Original approval plus efficacy supplements

Registered trials

89

37 Phase 3, 4 recruiting

FAERS reports

23,629

9,187 serious, 458 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.1) ] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.1) ] . PRISTIQ is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information...

What it is approved for

From the label in effect Apr 28, 2026.

PRISTIQ is indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14) ] . PRISTIQ is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with major depressive disorder (MDD) ( 1 ).

Mechanism: The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective SNRI.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • PRISTIQ · DESVENLAFAXINE SUCCINATE EQ 100MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • PRISTIQ · DESVENLAFAXINE SUCCINATE EQ 25MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • PRISTIQ · DESVENLAFAXINE SUCCINATE EQ 50MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Desvenlafaxine" as an intervention, any sponsor and status, largest first.

All 89 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective2,459
  • nausea2,241
  • headache1,794
  • dizziness1,765
  • anxiety1,654
  • fatigue1,517
  • insomnia1,466
  • feeling abnormal1,383
  • depression1,238
  • drug withdrawal syndrome1,012
  • malaise972
  • diarrhoea862

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081,213
2009495
20104,881
20112,010
20122,244
20131,800
2014717
2015143
20161,718
20171,313
2018903
20191,054
2020918
2021434
20221,034
2023825
2024701
2025757
2026469

Recalls

1 FDA enforcement reports for this application.

  • Apr 16, 2014 · Class II · Terminated

    Presence of Foreign Tablets/Capsules: Pfizer is recalling 50 mg Pristiq (desvenlafaxine) extended release tablets because a single Pristiq 100 mg tablet was found in a bottle of 50 mg Pristiq.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pristiq (Desvenlafaxine Succinate)

2024 spending

$6.1M

Beneficiaries

1,470

7,562 claims

Per beneficiary

$4,121

$13.98 per unit

View as table
YearSpending
2020$10,668,530
2021$9,380,716
2022$7,767,776
2023$6,611,882
2024$6,057,588

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 125 on PubMed

Sponsor: Pf Prism Cv

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.